Navigation Links
TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients

SAN DIEGO, Jan. 31 /PRNewswire/ -- TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.


The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce V617F-expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction of V617F-expressing cell populations correlated with improved survival and reduced morbidity. There are no currently approved specific therapies for PV, ET and PMF. These disorders are estimated to affect approximately 200,000 patients in the United States and more than twice that total worldwide.

The current clinical trial is being conducted at multiple centers in the USA. The trial is expected to enroll between 40-80 patients. Primary goals of this open label dose escalating protocol include identification of a maximum tolerated dose (MTD), accumulation of safety data, measurement of drug effect on surrogate markers, biomarkers, and presumptive clinical endpoints.

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases.

TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Management, Pappas Ventures, CTI Life Sciences and other investors.

SOURCE TargeGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
(Date:12/1/2015)... MARIETTA, Ga. , Dec. 1, 2015 ... purchase Dallas, Texas -based Tenet Healthcare,s ... WellStar Board of Trustees approved the strategic move following ... expand upon its proven clinical care models and patient ... improved access to healthcare to new communities. ...
(Date:12/1/2015)...  Eyeon Therapeutics has received a Notice of ... on a charged hydrophilic polymer developed at Particles ... has been shown to be safe and effective ... Mitchnick , MD, CEO states, "This second set ... in conjunction with a therapeutic agent.  Nanoparticles coated ...
(Date:12/1/2015)... Pharma Tech Outlook recently conducted a comprehensive ... Management Solution Providers - 2015 .  After careful consideration ... CIOs, VCs, analysts, and the Pharma Tech Outlook editorial ... 10 clinical data management solution providers (check out the ... 36 respectively). --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile ... wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are ... of North America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... that it has been selected as a finalist in this year’s Fierce Innovation ... FierceMobileHealthcare. Next IT Healthcare was recognized as a finalist in the category of ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest ... Integration ,” addresses a main “pain point” for merging or aligning healthcare provider ... a deal is signed. This quick-read guidance suggests that failing to recognize ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
Breaking Medicine News(10 mins):